Keymed Biosciences receives USD 257 million upfront as Gilead completes Ouro Medicines acquisition

Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

0.00
  • Keymed Biosciences received an upfront payment of USD 257 million following completion of Ouro Medicines’ merger on June 5, 2026.
  • Gilead acquired 100% of Ouro Medicines for USD 1.68 billion upfront, with potential milestones of up to USD 500 million.
  • Keymed is eligible for up to about USD 70 million in milestones tied to its former Ouro stake.
  • A separate 2024 exclusive license with Ouro remains in force, with up to USD 610 million in milestones and tiered royalties to be paid by Gilead and Lakefront.
  • Lakefront took most Ouro operating assets, with Gilead leading late-stage studies and holding global commercialization rights outside Greater China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260605-12191585), on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.